全文获取类型
收费全文 | 876245篇 |
免费 | 71775篇 |
国内免费 | 2889篇 |
专业分类
耳鼻咽喉 | 12921篇 |
儿科学 | 24775篇 |
妇产科学 | 25254篇 |
基础医学 | 125810篇 |
口腔科学 | 25667篇 |
临床医学 | 77163篇 |
内科学 | 166517篇 |
皮肤病学 | 17069篇 |
神经病学 | 70803篇 |
特种医学 | 35640篇 |
外国民族医学 | 181篇 |
外科学 | 137614篇 |
综合类 | 27595篇 |
现状与发展 | 8篇 |
一般理论 | 264篇 |
预防医学 | 67732篇 |
眼科学 | 20839篇 |
药学 | 66234篇 |
15篇 | |
中国医学 | 2463篇 |
肿瘤学 | 46345篇 |
出版年
2018年 | 7780篇 |
2015年 | 8363篇 |
2014年 | 11907篇 |
2013年 | 17499篇 |
2012年 | 23792篇 |
2011年 | 25015篇 |
2010年 | 14690篇 |
2009年 | 13712篇 |
2008年 | 23346篇 |
2007年 | 25386篇 |
2006年 | 25269篇 |
2005年 | 24881篇 |
2004年 | 24171篇 |
2003年 | 23262篇 |
2002年 | 22312篇 |
2001年 | 36174篇 |
2000年 | 36767篇 |
1999年 | 31207篇 |
1998年 | 9408篇 |
1997年 | 8737篇 |
1996年 | 8633篇 |
1995年 | 8138篇 |
1994年 | 7826篇 |
1992年 | 26735篇 |
1991年 | 26167篇 |
1990年 | 25688篇 |
1989年 | 24733篇 |
1988年 | 23252篇 |
1987年 | 22918篇 |
1986年 | 21780篇 |
1985年 | 21114篇 |
1984年 | 16394篇 |
1983年 | 14003篇 |
1982年 | 8860篇 |
1981年 | 8203篇 |
1980年 | 7671篇 |
1979年 | 16740篇 |
1978年 | 12114篇 |
1977年 | 10181篇 |
1976年 | 9328篇 |
1975年 | 10147篇 |
1974年 | 12641篇 |
1973年 | 12136篇 |
1972年 | 11538篇 |
1971年 | 10685篇 |
1970年 | 10218篇 |
1969年 | 9909篇 |
1968年 | 8900篇 |
1967年 | 8230篇 |
1966年 | 7653篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
W. Dalton Dietrich 《Topics in spinal cord injury rehabilitation》2015,21(2):174-187
It was an honor for me to present the 2014 G. Heiner Sell Memorial Lecture at the annual American Spinal Injury Association (ASIA) meeting in San Antonio. For this purpose, I provided a comprehensive review of the scope of research targeting discovery and translational and clinical investigations into spinal cord injury (SCI) research. Indeed, these are exciting times in the area of spinal cord research and clinical initiatives. Many laboratories and clinical programs throughout the world are publishing data related to the pathophysiology of SCI and new strategies for protecting and promoting recovery in both animal models and humans. For this lecture, several topics were discussed including neuroprotective and reparative strategies, neurorehabilitation, quality of life issues, and future directions. In the area of neuroprotection, pathophysiological events that may be targeted with therapeutic strategies, including pharmacological and targeted temperature management were reviewed. For reparative approaches, the importance of both intrinsic and extrinsic mechanisms of axonal regeneration was highlighted. Various cell therapies currently being tested in preclinical and clinical arenas were reviewed as well as ongoing US Food and Drug Administration approved trials for SCI patients. Neurorehabilitation is an evolving research field with locomotive training strategies, electrical stimulation, and brain-machine interface programs targeting various types of SCI. The importance of testing combination approaches including neuroprotective, reparative, and rehabilitative strategies to maximize recovery mechanisms was therefore emphasized. Finally, quality of life issues that affect thousands of individuals living with paralysis were also presented. Future directions and specific obstacles that require attention as we continue to move the SCI field forward were discussed. 相似文献
63.
64.
Jeroen M. van de Pol Jurjen G. Geljon Svetlana V. Belitser Geert W.J. Frederix Anke M. Hövels Marcel L. Bouvy 《Research in social & administrative pharmacy》2019,15(1):70-76
Introduction
The nature of community pharmacy is changing, shifting from the preparation and distribution of medicines to the provision of cognitive pharmaceutical services (CPS); however, often the provision of traditional services leaves little time for innovative services. This study investigated the time community pharmacists spend on the tasks and activities of daily practice and to what extent they are able to implement CPS-related services in daily practice.Methods
Self-reporting work sampling was used to register the activities of community pharmacists. A smartphone application, designed specifically for this purpose, alerted participants to register their current activity five times per working day for 6 weeks. Participants also completed an online survey about baseline characteristics.Results
Ninety-one Dutch community pharmacists provided work-sampling data (7848 registered activities). Overall, 51.5% of their time was spent on professional activities, 35.4% on semi-professional activities, and 13.1% on non-professional activities. The proportion of time devoted to CPS decreased during the workweek, whereas the time spent on traditional task increased.Discussion and conclusion
This study shows it is feasible to collect work-sampling data using smartphone technology. Community pharmacists spent almost half of their time on semi-professional and non-professional activities, activities that could be delegated to other staff members. In practice, the transition to CPS is hampered by competing traditional tasks, which prevents community pharmacists from profiling themselves as pharmaceutical experts in daily practice. 相似文献65.
66.
67.
Wen Wang Yanmei Liu Chuan Yu Jing Tan Weiyi Xiong Duo Dong 《Expert opinion on drug safety》2020,19(3):339-347
ABSTRACTObjectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding.Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with cefoperazone-tazobactam or ceftazidime. Propensity-score matching was used to explore whether treatment with cefoperazone-sulbactam increased the risk of prothrombin time (PT) prolongation, coagulation disorders, and bleeding, or decreased platelets (PLT).Results: The cohort included 23,242 patients. Among patients receiving cefoperazone-sulbactam, the risk of PT prolongation, coagulation disorders, decreased PLT, and bleeding was 5.3%, 9.2%, 15.7%, and 4.2%, respectively. Propensity-score matching analyses suggested that cefoperazone-sulbactam increased the risk of PT prolongation (aOR 2.26, 95% CI 1.61–3.18), coagulation disorders (aOR 1.81, 95% CI 1.43–2.30), and decreased PLT (aOR 1.46, 95% CI 1.25–1.72), but not increase bleeding (aOR 1.05, 95% CI 0.79–1.40) compared with ceftazidime. Patients receiving cefoperazone-sulbactam had higher risk of PT prolongation (aOR 1.53, 95% CI 1.11–2.10), coagulation disorders (aOR 1.53, 95% CI 1.21–1.95), but not decreased PLT (aOR 0.93, 95% CI 0.81–1.07) or bleeding (aOR 1.11, 95% CI 0.87–1.42), compared with those receiving cefoperazone-tazobactam.Conclusion: Cefoperazone-sulbactam may be associated with a higher risk of PT prolongation and coagulation disorders compared with cefoperazone-tazobactam and ceftazidime. 相似文献
68.
69.
70.